{"id":"NCT02074345","sponsor":"Takeda","briefTitle":"Phase III Study of Intramuscular TAK-816 in Healthy Infants","officialTitle":"A Phase III, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of Intramuscular TAK-816 in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2014-02-28","resultsPosted":"2016-04-26","lastUpdate":"2016-04-26"},"enrollment":31,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Healthy Volunteers","Haemophilus Influenzae Type b, Prevention"],"interventions":[{"type":"BIOLOGICAL","name":"TAK-816","otherNames":[]}],"arms":[{"label":"TAK-816 0.5 mL","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and immunogenicity of intramuscular TAK-816 in healthy Japanese infants.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"For 64 Weeks","effectByArm":[{"arm":"TAK-816 0.5 mL","deltaMin":31,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":["29685594"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":31},"commonTop":["Nasopharyngitis","Pyrexia","Diarrhoea","Eczema","Injection site erythema"]}}